Founded in 1969, Pharmathen has become one of the largest, vertically integrated developers of complex drug delivery technologies. Pharmathen remains committed to its vision to improve people’s lives through innovation and access to affordable medicines. With best-in-class R&D capabilities, Pharmathen is working on one of the most advanced pipelines in the industry consisting of more than 40 products, focusing on long-acting injectables (LAI), sustained release and ophthalmic formulations produced in its US FDA and EU approved manufacturing facilities in Greece. Pharmathen’s product portfolio of more than 90 commercialized products is sold to 250 customers and accessed by patients in more than 90 countries worldwide. Pharmathen is constantly strengthening its portfolio with innovative technologies and Long-Acting Therapeutic Technologies (LATTs), due to the three fully certified technological platforms it has developed. As a result, Pharmathen can provide a wide range of therapies aimed at enhancing patient compliance for those previously receiving "conventional" treatment and create new Life Cycle Management (LCM) opportunities. Pharmathen maintains a strong presence in all major markets and collaborates with the most significant organizations in the global pharmaceutical market, with a broad partner network in more than 90 countries worldwide. The company ranks among the top 50 pharmaceutical research companies in Europe and is one of the largest private sector investors in R&D in Greece, with steady investments of €35m annually in the R&D sector. Pharmathen employs more than 1.450 people from over 24 different nationalities, with 52% of its total workforce being female and 70% of Pharmathen's Research Operations Team also being women. The company's enduring success is attributed to the passion for creativity, the ethics, and dedication of its people, who share the same values and remain committed to the company's vision of making a difference in people’s lives.